Future pandemics challenges the vaccine market

Advances in technology, production, research methods, and the need to provide the expanding world population with solutions to health concerns have led the vaccines industry to expanded and reverse its declining trend.
By: Barbora Kuckova
Oct. 14, 2010 - PRLog -- Future pandemics challenges the vaccine market

Press contact:
Barbora Kuckova
Marketing Executive
Jacob Fleming Group
Tel: +421 257 272 126

For many years there had been a decline in the development of new vaccines to treat some of the world most common diseases. Very often research and development being slow, trials being unsuccessful, and vaccines not being well received discouraging pharmaceutical companies. However by the turn of the century with the development of new technologies, production and research methods, and the need to provide the ever expanding world population with solutions to health concerns the industry has expanded and reversed its declining trend.

There have been substantial breakthroughs in research and development of vaccines to treat some of the most critical illnesses and diseases, as a result the future role of vaccines to treat outbreaks of diseases still play a very important role, much more so after recent outbreaks of diseases like swine flu. This has renewed interest in the development of next generation of vaccines.

Some of the leading pharmaceutical companies are increasing spending on the research and development of next generation vaccines which aim to cure the most common diseases and provide hope to millions as well as allowing them diversify their product portfolio to other parts of the world where there may be a greater need for vaccinations.

Fleming Europe’s conference on Next Generation Vaccines will take place at Hilton in Vienna, Austria on the 24th and 25th February 2011. It will be an opportunity to meet experts in the field. Paneled speakers include Michel Zaffran from WHO and Dr Satish D. Ravetkar from Serum Institute of India, who will be speaking about ideal attributes for vaccines for use in low and middle income countries. Dr Mansour Yaich from PATH will focus on maximizing vaccine accessibility benefits through strategic public - private partnerships, affordability and intellectual property. Together with representatives from four associations as well as world leading pharmaceutical companies such as Merck & Co., Novartis, Pfizer, Abbott Biologicals B.V.

Take part in a pre-conference workshop which will discuss accelerating the development process, consisting of all the crucial parts within the vaccine lifecycle. From research and development, labeling, supply chain management, to marketing strategies, and getting the final product to the end customer.

Industry professionals will also highlight how to prepare and plan for future pandemics. It will be a chance to improve commercial networks and to seek new business opportunities.

Should you decide to become one of the attendees please contact Barbora Kuckova on +421 257 272 126 or email barbora.kuckova@jacobfleming.com

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.
For more information visit www.jacobfleming.com

# # #

Specialised B2B conference producers, producing high quality, industry specific business events around the world. Fleming Europe Conferences is one of the leading names in business intelligence.
Source:Barbora Kuckova
Email:***@flemingeurope.com Email Verified
Tags:Vaccines, Medication, Health, Research, Development, Population, Africa, Asia, Disease, Pharmaceutical
Industry:Medication, Health
Account Email Address Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share